3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Buy
58
HLBBF Quote, Financials, Valuation and Earnings
Last price:
$6.15
Seasonality move
:
8.02%
Day range:
$6.15 - $6.15
52-week range:
$4.63 - $7.50
Dividend yield:
1.67%
P/E ratio:
15.58x
P/S ratio:
1.96x
P/B ratio:
1.71x
Volume:
--
Avg. volume:
123
1-year change:
28.13%
Market cap:
$6.1B
Revenue:
$2.9B
EPS (TTM):
$0.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HLBBF
H. Lundbeck AS
|
-- | -- | -- | -- | -- |
|
ASND
Ascendis Pharma AS
|
$101.1M | -$1.39 | -31.79% | -15.93% | $192.06 |
|
EVAX
Evaxion Biotech AS
|
$1.7M | -$0.03 | 2173.29% | -98% | -- |
|
GLTO
Galecto
|
-- | -$2.82 | -- | -51.46% | -- |
|
GMAB
Genmab AS
|
$888.1M | $0.39 | 29.3% | 152.67% | $36.56 |
|
IOBT
IO Biotech
|
-- | -$0.40 | -- | -0.65% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HLBBF
H. Lundbeck AS
|
$6.15 | -- | $6.1B | 15.58x | $0.10 | 1.67% | 1.96x |
|
ASND
Ascendis Pharma AS
|
$140.28 | $192.06 | $8.4B | -- | $0.00 | 0% | 22.57x |
|
EVAX
Evaxion Biotech AS
|
$0.95 | -- | $5.6M | -- | $0.00 | 0% | 1.32x |
|
GLTO
Galecto
|
$5.54 | -- | $7.3M | -- | $0.00 | 0% | -- |
|
GMAB
Genmab AS
|
$21.86 | $36.56 | $13.9B | 20.77x | $0.00 | 0% | 4.93x |
|
IOBT
IO Biotech
|
$0.90 | -- | $59.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HLBBF
H. Lundbeck AS
|
13.49% | 0.039 | 8.2% | 1.63x |
|
ASND
Ascendis Pharma AS
|
114.08% | 1.789 | 9.87% | 0.81x |
|
EVAX
Evaxion Biotech AS
|
-- | -1.703 | -- | 2.80x |
|
GLTO
Galecto
|
-- | 1.479 | -- | -- |
|
GMAB
Genmab AS
|
-- | 0.544 | -- | 5.15x |
|
IOBT
IO Biotech
|
-- | -1.627 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HLBBF
H. Lundbeck AS
|
$682M | $119.5M | 10.15% | 11.81% | 14.17% | $330.2M |
|
ASND
Ascendis Pharma AS
|
$51.3M | -$106.4M | -89.94% | -880.05% | -125.93% | -$110.6M |
|
EVAX
Evaxion Biotech AS
|
-- | -$1.7M | -238.97% | -- | -54.59% | -- |
|
GLTO
Galecto
|
-- | -$3.8M | -- | -- | -- | -$3.7M |
|
GMAB
Genmab AS
|
$776.2M | $312.3M | 14.86% | 14.86% | 31.35% | $301.5M |
|
IOBT
IO Biotech
|
-- | -$26.5M | -- | -- | -- | -$20.8M |
H. Lundbeck AS vs. Competitors
-
Which has Higher Returns HLBBF or ASND?
Ascendis Pharma AS has a net margin of 13.58% compared to H. Lundbeck AS's net margin of -171.53%. H. Lundbeck AS's return on equity of 11.81% beat Ascendis Pharma AS's return on equity of -880.05%.
Company Gross Margin Earnings Per Share Invested Capital HLBBFH. Lundbeck AS80.88% $0.11 $4.1B ASNDAscendis Pharma AS80.63% -$1.89 $772.2M -
What do Analysts Say About HLBBF or ASND?
H. Lundbeck AS has a consensus price target of --, signalling downside risk potential of --. On the other hand Ascendis Pharma AS has an analysts' consensus of $192.06 which suggests that it could grow by 36.4%. Given that Ascendis Pharma AS has higher upside potential than H. Lundbeck AS, analysts believe Ascendis Pharma AS is more attractive than H. Lundbeck AS.
Company Buy Ratings Hold Ratings Sell Ratings HLBBFH. Lundbeck AS0 0 0 ASNDAscendis Pharma AS11 1 0 -
Is HLBBF or ASND More Risky?
H. Lundbeck AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.145%.
-
Which is a Better Dividend Stock HLBBF or ASND?
H. Lundbeck AS has a quarterly dividend of $0.10 per share corresponding to a yield of 1.67%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. H. Lundbeck AS pays 25.15% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. H. Lundbeck AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLBBF or ASND?
H. Lundbeck AS quarterly revenues are $843.3M, which are larger than Ascendis Pharma AS quarterly revenues of $63.6M. H. Lundbeck AS's net income of $114.5M is higher than Ascendis Pharma AS's net income of -$109.1M. Notably, H. Lundbeck AS's price-to-earnings ratio is 15.58x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for H. Lundbeck AS is 1.96x versus 22.57x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLBBFH. Lundbeck AS1.96x 15.58x $843.3M $114.5M ASNDAscendis Pharma AS22.57x -- $63.6M -$109.1M
-
Which has Higher Returns HLBBF or EVAX?
Evaxion Biotech AS has a net margin of 13.58% compared to H. Lundbeck AS's net margin of -64.14%. H. Lundbeck AS's return on equity of 11.81% beat Evaxion Biotech AS's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HLBBFH. Lundbeck AS80.88% $0.11 $4.1B EVAXEvaxion Biotech AS-- -$0.40 $74K -
What do Analysts Say About HLBBF or EVAX?
H. Lundbeck AS has a consensus price target of --, signalling downside risk potential of --. On the other hand Evaxion Biotech AS has an analysts' consensus of -- which suggests that it could grow by 1117.11%. Given that Evaxion Biotech AS has higher upside potential than H. Lundbeck AS, analysts believe Evaxion Biotech AS is more attractive than H. Lundbeck AS.
Company Buy Ratings Hold Ratings Sell Ratings HLBBFH. Lundbeck AS0 0 0 EVAXEvaxion Biotech AS0 0 0 -
Is HLBBF or EVAX More Risky?
H. Lundbeck AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HLBBF or EVAX?
H. Lundbeck AS has a quarterly dividend of $0.10 per share corresponding to a yield of 1.67%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. H. Lundbeck AS pays 25.15% of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend. H. Lundbeck AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLBBF or EVAX?
H. Lundbeck AS quarterly revenues are $843.3M, which are larger than Evaxion Biotech AS quarterly revenues of $3M. H. Lundbeck AS's net income of $114.5M is higher than Evaxion Biotech AS's net income of -$1.9M. Notably, H. Lundbeck AS's price-to-earnings ratio is 15.58x while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for H. Lundbeck AS is 1.96x versus 1.32x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLBBFH. Lundbeck AS1.96x 15.58x $843.3M $114.5M EVAXEvaxion Biotech AS1.32x -- $3M -$1.9M
-
Which has Higher Returns HLBBF or GLTO?
Galecto has a net margin of 13.58% compared to H. Lundbeck AS's net margin of --. H. Lundbeck AS's return on equity of 11.81% beat Galecto's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HLBBFH. Lundbeck AS80.88% $0.11 $4.1B GLTOGalecto-- -$3.39 -- -
What do Analysts Say About HLBBF or GLTO?
H. Lundbeck AS has a consensus price target of --, signalling downside risk potential of --. On the other hand Galecto has an analysts' consensus of -- which suggests that it could grow by 80.51%. Given that Galecto has higher upside potential than H. Lundbeck AS, analysts believe Galecto is more attractive than H. Lundbeck AS.
Company Buy Ratings Hold Ratings Sell Ratings HLBBFH. Lundbeck AS0 0 0 GLTOGalecto0 0 0 -
Is HLBBF or GLTO More Risky?
H. Lundbeck AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HLBBF or GLTO?
H. Lundbeck AS has a quarterly dividend of $0.10 per share corresponding to a yield of 1.67%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. H. Lundbeck AS pays 25.15% of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend. H. Lundbeck AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLBBF or GLTO?
H. Lundbeck AS quarterly revenues are $843.3M, which are larger than Galecto quarterly revenues of --. H. Lundbeck AS's net income of $114.5M is higher than Galecto's net income of -$3.9M. Notably, H. Lundbeck AS's price-to-earnings ratio is 15.58x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for H. Lundbeck AS is 1.96x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLBBFH. Lundbeck AS1.96x 15.58x $843.3M $114.5M GLTOGalecto-- -- -- -$3.9M
-
Which has Higher Returns HLBBF or GMAB?
Genmab AS has a net margin of 13.58% compared to H. Lundbeck AS's net margin of 22.85%. H. Lundbeck AS's return on equity of 11.81% beat Genmab AS's return on equity of 14.86%.
Company Gross Margin Earnings Per Share Invested Capital HLBBFH. Lundbeck AS80.88% $0.11 $4.1B GMABGenmab AS95.07% $0.29 $4.8B -
What do Analysts Say About HLBBF or GMAB?
H. Lundbeck AS has a consensus price target of --, signalling downside risk potential of --. On the other hand Genmab AS has an analysts' consensus of $36.56 which suggests that it could grow by 67.23%. Given that Genmab AS has higher upside potential than H. Lundbeck AS, analysts believe Genmab AS is more attractive than H. Lundbeck AS.
Company Buy Ratings Hold Ratings Sell Ratings HLBBFH. Lundbeck AS0 0 0 GMABGenmab AS2 5 0 -
Is HLBBF or GMAB More Risky?
H. Lundbeck AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genmab AS has a beta of 0.966, suggesting its less volatile than the S&P 500 by 3.369%.
-
Which is a Better Dividend Stock HLBBF or GMAB?
H. Lundbeck AS has a quarterly dividend of $0.10 per share corresponding to a yield of 1.67%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. H. Lundbeck AS pays 25.15% of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend. H. Lundbeck AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLBBF or GMAB?
H. Lundbeck AS quarterly revenues are $843.3M, which are larger than Genmab AS quarterly revenues of $816.4M. H. Lundbeck AS's net income of $114.5M is lower than Genmab AS's net income of $186.6M. Notably, H. Lundbeck AS's price-to-earnings ratio is 15.58x while Genmab AS's PE ratio is 20.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for H. Lundbeck AS is 1.96x versus 4.93x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLBBFH. Lundbeck AS1.96x 15.58x $843.3M $114.5M GMABGenmab AS4.93x 20.77x $816.4M $186.6M
-
Which has Higher Returns HLBBF or IOBT?
IO Biotech has a net margin of 13.58% compared to H. Lundbeck AS's net margin of --. H. Lundbeck AS's return on equity of 11.81% beat IO Biotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HLBBFH. Lundbeck AS80.88% $0.11 $4.1B IOBTIO Biotech-- -$0.36 -- -
What do Analysts Say About HLBBF or IOBT?
H. Lundbeck AS has a consensus price target of --, signalling downside risk potential of --. On the other hand IO Biotech has an analysts' consensus of -- which suggests that it could grow by 902%. Given that IO Biotech has higher upside potential than H. Lundbeck AS, analysts believe IO Biotech is more attractive than H. Lundbeck AS.
Company Buy Ratings Hold Ratings Sell Ratings HLBBFH. Lundbeck AS0 0 0 IOBTIO Biotech0 0 0 -
Is HLBBF or IOBT More Risky?
H. Lundbeck AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IO Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HLBBF or IOBT?
H. Lundbeck AS has a quarterly dividend of $0.10 per share corresponding to a yield of 1.67%. IO Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. H. Lundbeck AS pays 25.15% of its earnings as a dividend. IO Biotech pays out -- of its earnings as a dividend. H. Lundbeck AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLBBF or IOBT?
H. Lundbeck AS quarterly revenues are $843.3M, which are larger than IO Biotech quarterly revenues of --. H. Lundbeck AS's net income of $114.5M is higher than IO Biotech's net income of -$24M. Notably, H. Lundbeck AS's price-to-earnings ratio is 15.58x while IO Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for H. Lundbeck AS is 1.96x versus -- for IO Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLBBFH. Lundbeck AS1.96x 15.58x $843.3M $114.5M IOBTIO Biotech-- -- -- -$24M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 30.64% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is up 22.41% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is up 18.99% over the past day.
